UK markets open in 1 hour 55 minutes

Hutchison China MediTech Limited (HCM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.65-0.24 (-1.73%)
At close: 04:00PM EDT
13.41 -0.24 (-1.76%)
After hours: 07:46PM EDT

Hutchison China MediTech Limited

Cheung Kong Center
48th Floor 2 Queen's Road
Central
Hong Kong
852 2128 1188
https://www.hutch-med.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees2,110

Key executives

NameTitlePayExercisedYear born
Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBAExec. Chairman85kN/A1952
Dr. Weiguo Su B.Sc., Ph.D.CEO, Chief Scientific Officer & Exec. Director1.36MN/A1957
Mr. Chig Fung Cheng BEc, CACFO & Exec. Director838.51kN/A1967
Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, EdM, SolicitoCompany Sec. & Non-Exec. Director74.3kN/A1952
Dr. Karen Jane AtkinExec. VP & COON/AN/A1966
Mr. Kin Hung Lee M.B.A.Sr. VP of Corp. Fin. & Devel.N/AN/A1977
Mr. Charles George Rupert NixonGroup Gen. CounselN/AN/A1970
Ms. Selina ZhangSr. VP of Global HRN/AN/AN/A
Dr. Qingmei Wang Ph.D.Sr. VP of Bus. Devel. & Strategic AlliancesN/AN/A1963
Mr. Hong ChenSr. VP & Chief Commercial Officer- ChinaN/AN/A1970
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Corporate governance

Hutchison China MediTech Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.